Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.

Buzzword News

Mar 28, 2025 - 06:45

0 1

Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.

Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.

Tags:

What's Your Reaction?

Related Posts

Popular Posts

Recommended Posts

Popular Tags